Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$15.85 USD
-0.19 (-1.18%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $15.95 +0.10 (0.63%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.85 USD
-0.19 (-1.18%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $15.95 +0.10 (0.63%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Zacks News
QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform
by Zacks Equity Research
QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
Here's Why Omnicell (OMCL) Should be in Your Portfolio Now
by Zacks Equity Research
A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).
Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes
by Zacks Equity Research
For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.
ICON (ICRL) Gains From Strategic Acquisitions, Innovation
by Zacks Equity Research
In addition to its focused efforts within the biotech segment, ICON (ICLR) continues to drive forward its leadership in large pharma.
Here's Why Thermo Fisher (TMO) Should be in Your Portfolio
by Zacks Equity Research
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Henry Schein (HSIC) Banks on Global Expansion Amid Macro Issues
by Zacks Equity Research
Within the Dental business, Henry Schein (HSIC) is aiming to deliver customized solutions, leveraging market insights and technological advancements.
IDEXX (IDXX) Expands Test Menu for the Catalyst Platform
by Zacks Equity Research
IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.
5 Phenomenal Relative Price Strength Stocks to Snap Up Now
by Nilanjan Choudhury
VITL, HIMS, ANF, CHWY and GPS are five stocks with explosive relative price strength.
Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu
by Zacks Equity Research
QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).
Zimmer Biomet (ZBH) Procedure Recovery Aids Amid Macro Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to record strong procedure volume in 2024 in both the Knees and Hips businesses, banking on an improved market scenario.
Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System
by Zacks Equity Research
Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
by Zacks Equity Research
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
by Zacks Equity Research
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay
by Zacks Equity Research
The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
by Zacks Equity Research
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.
Charles River (CRL) Launches Viral Vector Tech Transfer Program
by Zacks Equity Research
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
SenesTech (SNES) to Gain Market With Evolve's Launch on Amazon
by Zacks Equity Research
SenesTech (SNES) looks to leverage the convenience and reach of e-commerce to expand its market share.
Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
by Zacks Equity Research
Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.
Reasons to Hold Charles River (CRL) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
by Zacks Equity Research
Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.